Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia–lymphoma cells

[1]  H. Drexler,et al.  Establishment and characterization of human B cell precursor-leukemia cell lines. , 1998, Leukemia research.

[2]  H. Koeffler,et al.  Methylation of the p16INK4A gene in multiple myeloma , 1998, British journal of haematology.

[3]  B. Quesnel,et al.  Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. , 1998, Blood.

[4]  M. Tomonaga,et al.  The methylthioadenosine phosphorylase gene is frequently co‐deleted with the p16INK4a gene in acute type adult T‐cell leukemia , 1998, International journal of cancer.

[5]  K. Spirin,et al.  Analysis of p18INK4C in adult T‐cell leukaemia and non‐Hodgkin's lymphoma , 1997, British journal of haematology.

[6]  M. Eguchi,et al.  Alterations of p16 and p15 genes in acute leukemia with MLL gene rearrangements and their correlation with clinical features , 1997, Leukemia.

[7]  M. Iravani,et al.  Methylation of the multi tumor suppressor gene-2 (MTS2, CDKN1, p15INK4B) in childhood acute lymphoblastic leukemia , 1997, Oncogene.

[8]  P. Jonveaux,et al.  De novo methylation of tumour suppressor genes CDKN2A and CDKN2B is a rare finding in B‐cell chronic lymphocytic leukaemia , 1997, British journal of haematology.

[9]  M. González,et al.  Deletions and rearrangements of cyclin-dependent kinase 4 inhibitor gene p16 are associated with poor prognosis in B cell non-Hodgkin’s lymphomas , 1997, Leukemia.

[10]  F. Sigaux,et al.  Disruption of the multiple tumor suppressor gene MTS1/p16(INK4a)/CDKN2 by illegitimate V(D)J recombinase activity in T-cell acute lymphoblastic leukemias. , 1997, Blood.

[11]  W. Hiddemann,et al.  Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. , 1997, Cancer research.

[12]  R. Herrmann,et al.  MTS1 expression and prognosis in acute myeloid leukemia , 1997, Annals of Hematology.

[13]  R. Rimokh,et al.  Molecular analysis of cyclin-dependent kinase inhibitors in human leukemias , 1997, Leukemia.

[14]  J. Benítez,et al.  Frequent allelic losses of 9p21 markers and low incidence of mutations at p16(CDKN2) gene in non-Hodgkin lymphomas of B-cell lineage. , 1997, Cancer genetics and cytogenetics.

[15]  H. Koeffler,et al.  Inhibition of growth of human leukemia cell lines by retrovirally expressed wild-type p16INK4A , 1997, Leukemia.

[16]  T. Kinoshita,et al.  Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. , 1997, Blood.

[17]  F. Behm,et al.  Genetic studies of childhood acute lymphoblastic leukemia with emphasis on p16, MLL, and ETV6 gene abnormalities: results of St Jude Total Therapy Study XII , 1997, Leukemia.

[18]  M. Tomonaga,et al.  Extensive analysis of the retinoblastoma gene in adult T cell leukemia/lymphoma (ATL) , 1997, Leukemia.

[19]  P. Burton,et al.  Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome. , 1997, Blood.

[20]  H. Koeffler,et al.  p21WAF1 mutations and human malignancies. , 1997, Leukemia & lymphoma.

[21]  M. Amylon,et al.  Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions. , 1997, Leukemia research.

[22]  M. Tomonaga,et al.  Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  H. Findley,et al.  Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. , 1997, Blood.

[24]  M. Ng,et al.  Frequent hypermethylation of p16 and p15 genes in multiple myeloma. , 1997, Blood.

[25]  J. Herman,et al.  DNA methylation changes in hematologic malignancies: biologic and clinical implications. , 1997, Leukemia.

[26]  C. Bartram,et al.  Molecular analysis of the cyclin-dependent kinase inhibitor genes, p15, p16, p18 and p19 in the myelodysplastic syndromes. , 1997, Leukemia research.

[27]  M. Link,et al.  Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. , 1997, Cancer research.

[28]  J. Herman,et al.  Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. , 1997, Cancer research.

[29]  J. Goldman,et al.  The commonly deleted region at 9p21-22 in lymphoblastic leukemias spans at least 400 kb and includes p16 but not p15 or the IFN gene cluster , 1997, Leukemia.

[30]  Carl W. Miller,et al.  Analysis of the p16INK4A, p15INK4B and p18INK4C genes in multiple myeloma , 1997, British journal of haematology.

[31]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[32]  M. Tomonaga,et al.  Alterations of the cyclin-dependent kinase inhibitor p19 (INK4D) is rare in hematopoietic malignancies. , 1996, Leukemia.

[33]  R. Siebert,et al.  Role of the cyclin-dependent kinase 4 and 6 inhibitor gene family p15, p16, p18 and p19 in leukemia and lymphoma. , 1996, Leukemia & lymphoma.

[34]  B. Quesnel,et al.  Transfer of p16inka/CDKN2 gene in leukaemic cell lines inhibits cell proliferation , 1996, British journal of haematology.

[35]  M. Diccianni,et al.  Frequent deletion in the methylthioadenosine phosphorylase gene in T-cell acute lymphoblastic leukemia: strategies for enzyme-targeted therapy. , 1996, Blood.

[36]  K. Anderson,et al.  A novel pre-B acute lymphoblastic leukemia cell line with chromosomal translocation between p16(INK4A)/p15(INK4B) tumor suppressor and immunoglobulin heavy chain genes: TGFbeta/IL-7 inhibitory signaling mechanism. , 1996, Leukemia.

[37]  M. Heyman,et al.  Inactivation of the p15INK4B and p16INK4 genes in hematologic malignancies. , 1996, Leukemia & lymphoma.

[38]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[39]  F. Dammacco,et al.  p16 gene analysis in multiple myeloma (MM). , 1996, Leukemia.

[40]  Y. Hayashi,et al.  Homozygous deletions of p16/MTS1 and p15/MTS2 genes are frequent in t(1;19)-negative but not in t(1;19)-positive B precursor acute lymphoblastic leukemia in childhood. , 1996, Leukemia.

[41]  S. Ogawa,et al.  Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies. , 1996, Blood.

[42]  F. Ragione,et al.  p16INK4A gene homozygous deletions in human acute leukaemias with alterations of chromosome 9 , 1996, British journal of haematology.

[43]  U. Kees,et al.  Deletions of the p16 gene in pediatric leukemia and corresponding cell lines. , 1996, Oncogene.

[44]  L. Chin,et al.  Role of the INK4a Locus in Tumor Suppression and Cell Mortality , 1996, Cell.

[45]  S. Smith,et al.  Deletion or lack of expression of CDKN2 (CDK4I/MTS1/INK4A) and MTS2 (INK4B) in acute lymphoblastic leukemia cell lines reflects the phenotype of the uncultured primary leukemia cells. , 1996, Leukemia.

[46]  R. Jamal,et al.  Variable expression of p16 protein in patients with acute myeloid leukemia without gross rearrangements at the DNA level. , 1996, Leukemia.

[47]  F. Sigaux,et al.  Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia. , 1996, Blood.

[48]  J. Herman,et al.  Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. , 1996, Cancer research.

[49]  R. Siebert,et al.  Analysis of the novel cyclin-dependent kinase 4 and 6 inhibitor gene p18 in lymphoma and leukemia cell lines. , 1996, Leukemia research.

[50]  M. Raffeld,et al.  Absence of p18 mutations or deletions in lymphoid malignancies. , 1996, Leukemia.

[51]  H. Kaneko,et al.  Alterations of CDKN2 gene structure in childhood acute lymphoblastic leukemia: mutations of CDKN2 are observed preferentially in T lineage. , 1996, Leukemia.

[52]  N. Cross,et al.  Mutational analysis of the p15 and p16 genes in acute leukaemias , 1996, British journal of haematology.

[53]  A. Iolascon,et al.  Homozygous deletions of cyclin-dependent kinase inhibitor genes, p16(INK4A) and p18, in childhood T cell lineage acute lymphoblastic leukemias. , 1996, Leukemia.

[54]  H. Cavé,et al.  Deletion mapping indicates that MTS1 is the target of frequent deletions at chromosome 9p21 in paediatric acute lymphoblastic leukaemias , 1996, British journal of haematology.

[55]  M. Skolnick,et al.  CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. , 1995, Oncogene.

[56]  O. Olopade,et al.  CDKN2 gene deletion is not found in chronic lymphoid leukaemias of B‐ and T‐cell origin but is frequent in acute lymphoblastic leukaemia , 1995, British journal of haematology.

[57]  E. Newcomb,et al.  Alterations of multiple tumor suppressor genes (p53 (17p13), p16INK4 (9p21), and DBM (13q14)) in B‐CELL chronic lymphocytic leukemia , 1995, Molecular carcinogenesis.

[58]  A. Iolascon,et al.  High frequency of homozygous deletions of CDK4I gene in childhood acute lymphoblastic leukaemia , 1995, British journal of haematology.

[59]  F. Ragione,et al.  Involvement of the cyclin‐dependent kinase‐4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia , 1995, British journal of haematology.

[60]  T. Kinoshita,et al.  Mutational analysis of the CDKN2 (MTS1/p16ink4A) gene in primary B-cell lymphomas. , 1995, Blood.

[61]  R. Siebert,et al.  Homozygous loss of the MTSl/pl6 and MTS2/pl5 genes in lymphoma and lymphoblastic leukaemia cell lines , 1995, British journal of haematology.

[62]  Carl W. Miller,et al.  Structural integrity of the cyclin‐dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias , 1995, British journal of haematology.

[63]  O. Olopade,et al.  Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies. , 1995, Blood.

[64]  M. Minden,et al.  p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines. , 1995, Leukemia & lymphoma.

[65]  H. Koeffler,et al.  Deletions of the cyclin-dependent kinase inhibitor genes p16INK4A and p15INK4B in non-Hodgkin's lymphomas. , 1995, Blood.

[66]  S. Ogawa,et al.  Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. , 1995, Blood.

[67]  Y. Hayashi,et al.  Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. , 1995, Blood.

[68]  H. Koeffler,et al.  Role of the cyclin-dependent kinase inhibitors in the development of cancer. , 1995, Blood.

[69]  C. Bartram,et al.  Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. , 1995, Blood.

[70]  C. Bréchot,et al.  Alterations of cyclin-dependent kinase 4 inhibitor (p16INK4A/MTS1) gene structure and expression in acute lymphoblastic leukemias. , 1995, Leukemia.

[71]  T. Manshouri,et al.  p16INK4A and p15INK4B gene deletions in primary leukemias. , 1995, Blood.

[72]  C. James,et al.  Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene in cell lines established from children with acute lymphoblastic leukemia. , 1995, Leukemia.

[73]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[74]  F. Keith,et al.  Abnormalities of retinoblastoma gene expression in hematological malignancies. , 1995, Leukemia & lymphoma.

[75]  F. Mandelli,et al.  Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. , 1995, Blood.

[76]  M. Tomonaga,et al.  Homozygous deletions of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia. , 1995, Blood.

[77]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[78]  D N Shapiro,et al.  Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4 , 1995, Molecular and cellular biology.

[79]  J. Goldman,et al.  Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. , 1995, Blood.

[80]  D. Longo,et al.  Detection of p53 mutations in B cell non-Hodgkin's lymphoma cell lines. , 1995, Leukemia.

[81]  M. Raffeld,et al.  Involvement of CDKN2 (p16INK4A/MTS1) and p15INK4B/MTS2 in human leukemias and lymphomas. , 1995, Cancer research.

[82]  J. Bartek,et al.  Aberrations of p16Ink4 and retinoblastoma tumour‐suppressor genes occur in distinct sub‐sets of human cancer cell lines , 1995, International journal of cancer.

[83]  A. Borkhardt,et al.  Recurrent chromosomal translocations and fusion genes in leukemia-lymphoma cell lines. , 1995, Leukemia.

[84]  C. D. Edwards,et al.  Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. , 1995, Cancer research.

[85]  B. Quesnel,et al.  p16 gene homozygous deletions in acute lymphoblastic leukemia. , 1995, Blood.

[86]  G. Gaidano,et al.  Diffuse large cell lymphomas exhibit frequent deletions in 9p21–22 and 9q31–34 regions , 1995, Genes, chromosomes & cancer.

[87]  C. Sherr.  G1 phase progression: Cycling on cue , 1994, Cell.

[88]  H. Koeffler,et al.  p53 in hematologic malignancies. , 1994, Blood.

[89]  K. Tanaka,et al.  Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias. , 1994, Blood.

[90]  Gregory J. Hannon,et al.  pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest , 1994, Nature.

[91]  Peter A. Jones,et al.  P16 gene in uncultured tumours , 1994, Nature.

[92]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[93]  C. Harris,et al.  p53: at the crossroads of molecular carcinogenesis and risk assessment. , 1993, Science.

[94]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[95]  F. Lanza,et al.  The abnormal p53 proteins expressed in CML cell lines are non-functional. , 1993, Leukemia.

[96]  Charles J. Sherr,et al.  Mammalian G1 cyclins , 1993, Cell.

[97]  H. Findley,et al.  Expression and Regulation of Bcl-2 , Bcl-xl , and Bax Correlate With p 53 Status and Sensitivity to Apoptosis in Childhood Acute Lymphoblastic Leukemia , 1997 .

[98]  M. Fey,et al.  Expression and regulation of G1 cell-cycle inhibitors (p16INK4A , p15INK4B, p18 INK4C, p19INK4D ) in human acute myeloid leukemia and normal myeloid cells , 1997, Leukemia.

[99]  M. Roussel,et al.  Features of macrophage differentiation induced by p19INK4d, a specific inhibitor of cyclin D-dependent kinases. , 1997, Blood.

[100]  J. Decaprio,et al.  Promotes Differentiation and Inhibits Apoptosis of JKB Acute Lymphoblastic Leukemia Cells , 1997 .

[101]  F. Ragione,et al.  Inactivation of cyclin-dependent kinase inhibitor genes and development of human acute leukemias. , 1997, Leukemia & lymphoma.

[102]  O. Olopade,et al.  CDKN2 Deletions in Leukemia-Derived Cell Lines: Detection by Fluorescence In Situ Hybridization with Interphase Cells , 1997 .

[103]  J. Bartek,et al.  Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin’s lymphomas. Functional studies in a cell line (Granta 519) , 1997, Leukemia.

[104]  M. Williams,et al.  Analysis of the cyclin-dependent kinase inhibitors p18 and p19 in mantle-cell lymphoma and chronic lymphocytic leukemia. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[105]  E. Campo,et al.  Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. , 1997, Blood.

[106]  S. Bohlander,et al.  TEL-AML1 translocations with TEL and CDKN2 inactivation in acute lymphoblastic leukemia cell lines. , 1996, Blood.

[107]  Y. Xiong,et al.  Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma. , 1995, Blood.

[108]  A. Knudson,et al.  Mutation and cancer: a personal odyssey. , 1995, Advances in cancer research.

[109]  F. Kaye,et al.  Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. , 1994, Oncogene.

[110]  S. Bi,et al.  p53 in chronic myeloid leukemia cell lines. , 1992, Leukemia.

[111]  W. Graham.  Deletions of interferon genes in acute lymphoblastic leukemia. , 1990, The New England journal of medicine.

[112]  R. D. Ouellette,et al.  ATL , 1984, Regional Anesthesia & Pain Medicine.

[113]  木下 研一郎,et al.  Adult T-cell Leukemia-Lymphoma (ATLL)の臨床的問題点 , 1983 .